New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXIII)

Monday, October 23
8:45-10:30 AM

Vancouver, BC

Chair: Paul W. Armstrong

Co-Chair: Justin Ezekowitz

2017 Sponsors
of New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXI)

This symposium was co-developed with the Canadian Cardiovascular Society, Mazankowski Alberta Heart Institute/University of Alberta, Canadian VIGOUR Centre, Novartis Pharmaceuticals Inc., and Bayer Inc., and was planned to ensure the evidence presented is valid, objective and balanced.



New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXIII)


Monday, October 23, 2017


Learning Objectives

  • Develop a management strategy for patients with heart failure across a spectrum of ejection fractions and with or without atrial fibrillation.
  • Formulate how to incorporate sacubitril/valsartan and ivabradine into clinical practice.
  • Apply an appropriate strategy for adding or deleting older therapies in heart failure.
  • Craft an evidence-based approach to modifying diabetes-related medications for patients with or at risk for heart failure.
  • Incorporate new knowledge in acute and chronic heart failure into current patient care.